TBG project Robert Fürst and team

Natural Products Genomics

Preclinical in vitro testing of natural compounds

Institution: Institute of Pharmaceutical Biology, Goethe University Frankfurt

TBG group members

  • Prof. Dr. Robert Fürst
  • Dr. Rebecca Ingelfinger, postdoc (01.07.2018 – 24.05.2020, parental leave)
  • Dr. Pelin Erkoc-Erik, postdoc (25.05.2020 – 30.09.2021, parental leave substitute)

TBG project summary

Natural compounds are chemical substances produced by living organisms. Due to their ability to interact with biological systems, they are very well suited as lead structures in drug discovery. Their importance is demonstrated in particular by the fact that two thirds of all approved drugs are directly related to natural compounds. Our project aims at preclinically investigating natural compounds discovered within the LOEWE TBG consortium in the field of inflammation and tumor angiogenesis. We will focus on the effect of these compounds on endothelial cells. Functional in vitro screening assays will be used to test the ability of natural compounds to affect the interaction of leukocytes with activated endothelial cells and angiogenesis-associated processes. The most interesting bioactive natural compounds will then be investigated for their mechanisms of action in the further course of the TBG group.

Group expertise / Methods

  • Inflammation
  • Angiogenesis
  • tumor metastasis
  • human cell culture
  • cell biology
  • biochemistry and molecular biology
  • functional in vitro test systems
  • high-content, medium throughput screening
  • identification of the underlying molecular mechanisms
  • molecular pharmacology